Developing new medicines is risky and costly. Recent public market volatility has led the $XBI (ETF that tracks the performance of the S&P® Biotechnology Index) to fall 60% from its 2021 high to the 2022 trough. In this light, biotech companies need to be creative in obtaining financing to support the development of needed medicines. In this session, Alok Tayi, founder of VIBE Bio DAO, will discuss innovative ways of capitalizing on programs & companies such that the organization has the resources required to help patients with novel medicines.